Skip to content
thestock.space

On 6 Nov 2026, Mahamaya Lifesciences was priced at ₹182.00, or 21.8× trailing earnings, against an industry P/E of 14.4×, and the shares are 11% below their 52-week high. Sales and net profit grew 34% and 64% a year over 3 years; its ROCE of 25% is the second-highest among the 7 largest Agricultural Inputs peers. Debt is 0.74× equity. It is listed on an SME platform with a market cap of ₹426 Cr, ranked 41st of 72 Agricultural Inputs companies by market cap; the shares rose 57% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2025.How we calculate this

past year
Open
₹179.15
Day high
₹182.00
Day low
₹178.20
Prev. close
₹179.15
Volume
3.6K

Health check

3 good · 1 fair · 2 to check
  • ReturnsAhead

    +56.9% over a year, better than 7 of 7 peers.

  • Price tagPricier

    P/E 21.8 vs industry 14.4.

  • GrowthStrong

    Sales +33.9%, profit +63.9% a year over 3 years.

  • ProfitabilityStrong

    ROCE 24.6% vs peer median 20.9%.

  • Balance sheetFair

    Debt 0.74× equity, interest covered 4.2×, Piotroski 5 of 9.

  • Red flags1 to check

    P/E of 21.8 against an industry P/E of 14.4.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Agricultural Inputs

71 listed peers. Screen the industry

Small cap

₹426 Cr, #41 of 72 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2025: sales ₹329 Cr · profit ₹17 Cr
Market cap
₹426 Cr
Small cap
P/E
21.8
Industry 14.4
Price to book
3.49
Peers 4.28
Dividend yield
0.00%
ROE
19.3%
Peers 16.2%
ROCE
24.6%
Peers 20.9%
Debt to equity
0.74
Debt ₹91 Cr
EPS (TTM)
₹8.33
OPM (TTM)
11.2%
Net margin 5.0%
Sales growth
+39.6%
Latest quarter vs a year ago
Profit growth
+19.5%
Latest quarter vs a year ago
Price to sales
1.29
EV/EBITDA 13.8

Strengths and risks

Strengths

  • Return on equity of 19.3%.
  • Return on capital employed of 24.6%.
  • Quarterly sales up 39.6% on a year ago.

Risks to check

  • P/E of 21.8 against an industry P/E of 14.4.

Derived automatically from reported figures. Not a recommendation.

About Mahamaya Lifesciences

Mahamaya Lifesciences Limited provides pesticides products in India. It offers high quality and effective agricultural crop protection solutions. The company also provides household pesticides, plant nutrition, and specialty chemicals. In addition, it exports its products. The company was incorporated in 2002 and is based in Gurugram, India.

Headquarters
Gurugram
Employees
71
Sector
Basic Materials
ISIN
INE0U9D01019
Website
mahamayalifesciences.com

Price range

52 weeks

₹111.00₹205.05

Today

₹178.20₹182.00
Avg volume (3M)
53K
1-year return
plus 56.9%
From 52-week high
minus 11.2%

Peers · Agricultural Inputs

Capital-heavy industry columns

Compare with peersScreen the whole industry
Company
COROMANDELCoromandel International1,824.00minus 4.00%53,72434.517.020.9%9.4%0.1110.2%minus 12.4%
FACTFertilisers and Chemicals Travancore750.25minus 1.24%48,547–703.514.2%0.0%2.950.0%minus 15.3%
UPLUPL534.90plus 1.60%45,21423.96.09.9%20.0%0.83−1.2%minus 28.0%
PIINDPI Industries1,735.00minus 1.98%26,32130.013.114.7%24.2%0.031.1%minus 51.9%
SUMICHEMSumitomo Chemical India328.95plus 0.34%16,41929.421.021.0%20.3%0.02−2.6%minus 34.4%
CHAMBLFERTChambal Fertilizers & Chemicals384.70minus 0.91%15,4138.15.721.8%13.7%0.16−9.2%minus 19.4%
BAYERCROPBayer Cropscience3,316.30plus 0.48%14,90420.015.427.9%16.0%0.033.6%minus 31.7%
MAHALIFEMahamaya Lifesciences182.00plus 1.59%42621.812.624.6%11.2%0.7433.9%plus 56.9%
Median of 7 peers–−0.91%26,32126.615.420.9%16.0%0.110.0%−28.0%

Quarterly results

Consolidated, ₹ crore · latest reported Jun 25
SalesSelect a row below to chart it
₹ CrJun 25
83
75.6
7.4
8.9%
0.7
1.8
0.5
5.7
27.9%
4.1
1.75

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+33.9%
Profit CAGR 3Y
+63.9%
ROE
19.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
137162264329
–+17.9%+63.5%+24.5%
128148239291
9.513.324.737.7
7.0%8.2%9.4%11.5%
−0.60.1−0.1−4
2.54.85.57.4
1.31.51.82.2
00−0.1−0.2
5.17.117.323.9
26.4%26.7%25.7%30.8%
3.85.212.816.5
–+39.1%+145.5%+29.0%
1.602.235.47–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1.21.217.823.4
18.223.431.798.5
24.454.658.190.7
34.132.880.897.6
77.9112188310
17.818.321.728.8
–––5.7
33439.4
57.190.8163236
77.9112188310

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1.1−22.7−0.4−29.5
−2.8−2−7.1−15.6
2.424.38.580.5
0.6−0.3135.4
−2.9−2.4−7.7−16.1
−1.8−25−8.1−45.6

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders. Institutions hold about 4.5% (Yahoo estimate).

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you